# VKTX — Viking Therapeutics · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** VKTX  
**Sources:** 22  
**Published:** 2026-10-28  
**Canonical:** https://app.k3vl4r.com/research/deep-research-vktx-viking-therapeutics-catalysts-narrative-risks-9820

---

# Viking Therapeutics (VKTX) — Point-in-Time Research Brief (as of 2026-11-11)

## Overview
Viking Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, focused on metabolic and endocrine disorders with an obesity-centric pipeline [[1]](https://www.morningstar.com/news/pr-newswire/20261021la77329/viking-therapeutics-to-report-financial-results-for-third-quarter-2026-on-october-28-2026), [[2]](https://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-two-poster-120500193.html). Its lead candidate, **VK2735**, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations [[1]](https://www.morningstar.com/news/pr-newswire/20261021la77329/viking-therapeutics-to-report-financial-results-for-third-quarter-2026-on-october-28-2026), [[2]](https://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-two-poster-120500193.html), [[20]](https://vikingtherapeutics.com/). It trades on the Nasdaq and is categorized among biotech names [[14]](https://squawknews.com/ticker/VKTX).

## Recent Catalysts (roughly Aug–Nov 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-vktx-viking-therapeutics-catalysts-narrative-risks-9820 (free to sign up)._
